WMSA
NRIX icon

Weiss Multi-Strategy Advisers’s Nurix Therapeutics NRIX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-51,714
Closed -$1.8M – 760
2020
Q3 		$1.8M Buy
+51,714
New +$1.3M 0.05% 363

Other funds holding NRIX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Weiss Multi-Strategy Advisers's NRIX Position: Q4 2020 in Review

Weiss Multi-Strategy Advisers sold out of Nurix Therapeutics (NRIX) in Q4 2020, closing a stake of 51,714 shares — an estimated $1.8M sold.

Weiss Multi-Strategy Advisers first reported a position in NRIX in Q3 2020 and held it in 1 quarter. The position peaked at $1.8M in Q3 2020. 68 funds tracked by Wall St. Rank hold NRIX as of Q4 2020.

  • Weiss Multi-Strategy Advisers reported no remaining Nurix Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 51,714 Nurix Therapeutics shares in Q4 2020, an estimated $1.8M.
  • Weiss Multi-Strategy Advisers first reported a position in Nurix Therapeutics in Q3 2020 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Nurix Therapeutics position peaked at $1.8M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2020.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.